Cliff Asness’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.71M Buy
1,220,949
+1,135,495
+1,329% +$3.39M ﹤0.01% 2198
2026
Q1
$263K Buy
85,454
+64,307
+304% +$273K ﹤0.01% 3471
2025
Q4
$76.3K Buy
+21,147
New +$92.2K ﹤0.01% 3480
2025
Q1
Sell
-12,577
Closed -$90.7K 3151
2024
Q4
$90.7K Sell
12,577
-11,308
-47% -$86.4K ﹤0.01% 2775
2024
Q3
$147K Sell
23,885
-17,494
-42% -$119K ﹤0.01% 2618
2024
Q2
$275K Sell
41,379
-19,315
-32% -$143K ﹤0.01% 2304
2024
Q1
$618K Buy
+60,694
New +$617K ﹤0.01% 1878
2023
Q2
Sell
-21,662
Closed -$91.4K 2184
2023
Q1
$91.4K Buy
+21,662
New +$257K ﹤0.01% 2122

Other funds holding ALT

Cliff Asness's ALT Position: Q2 2026 in Review

Cliff Asness increased its Altimmune (ALT) stake by 1,329% in Q2 2026, buying an estimated $3.39M and bringing the position to 1,220,949 shares worth $3.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

Cliff Asness first reported a position in ALT in Q1 2023 and has held it in 8 quarters since. 209 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Cliff Asness held 1,220,949 shares of Altimmune worth $3.71M as of Q2 2026.
  • Cliff Asness bought 1,135,495 Altimmune shares in Q2 2026, an estimated $3.39M.
  • Altimmune made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2198 holding.
  • Cliff Asness first reported a position in Altimmune in Q1 2023 and has held it in 8 quarters since.
  • 209 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.